Abstract
Tumors develop in a highly interactive cellular and humoral milieu known as the immune microenvironment. Under normal circumstances, the immune system efficiently eliminates cells that are hobbled by mutations. But, in relatively rare cases, proliferating cells can acquire an ability to manipulate their microenvironment so that the normal immune responses are held in check. Recent insights into the delicate interplay between evolving malignancies and the immune system have led to promising new treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Alzhanova D, Corcoran K, Bailey AG, Long K et al (2021) Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. PLoS Pathog 17:e1009033
Bashyam H (2007) CTLA-4: from conflict to clinic. J Exp Med 204:1243
Blagih J, Buck MD, Vousden KH (2020) p53, cancer and the immune response. J Cell Sci 133:jcs237453
Cha J-H, Chan L-C, Li C-W, Hsu JL, Hung M-C (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76:359–370
Galon J, Bruni D (2020) Tumor immunology and tumor evolution: intertwined histories. Immunity 52:55–81
Gutiérrez-Vázquez C, Quintana FJ (2018) Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48:19–33
Levine AJ (2020) P53 and the immune response: 40 years of exploration—a plan for the future. Int J Mol Sci 21:541
Motwani M, Pesiridis S, Fitzgerald KA (2019) DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Genet 20:657–674
Munn DH, Mellor AL (2016) IDO in the tumor microenvironment: inflammation, counter-regulation and tolerance. Trends Immunol 37:193–207
O’Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16:151–167
Old LJ (1977) Cancer immunology. Sci Am 236:62–79
Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807–839
Platten M, Nollen EAA, Röhrig UF, Fallarino F, Opitz CA (2019) Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Disc 18:379–401
Ribatti D (2017) The concept of immune surveillance against tumors: the first theories. OncoTarget 9:7175
Rothhammer V, Quintana FJ (2019) The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol 19:184–197
Schiering C, Wincent E, Metidji A, Iseppon A, Li Y, Potocnik AJ, Omenetti S, Henderson CJ, Wolf R, Nebert DW, Stockinger B (2017) Feedback control of AHR signalling regulates intestinal immunity. Nature 542:242–245
Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19:200–218
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev. Immunol 20:651–668
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bunz, F. (2022). Cancer and the Immune System. In: Principles of Cancer Genetics. Springer, Cham. https://doi.org/10.1007/978-3-030-99387-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-99387-0_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99386-3
Online ISBN: 978-3-030-99387-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)